Today, I’ll be speaking to state-wide leaders in California regarding the state’s fight against obesity.
Most Recent Posts
This year, biopharmaceutical companies committed to transforming how their clinical research can be used to advance innovation for patients through careful sharing of clinical trial data with independent researchers.
More than 30 million Americans suffer from rare diseases – conditions that are classified as such because they affect fewer than 200,000 people in the United States.
Earlier this month, Bill Chin announced on this blog that PhRMA will be hosting a forum along with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation on Wednesday, October 23rd.
Tuesday began Medicare Part D Open Enrollment. With the program still going strong 10 years after it was enacted, Part D represents a significant milestone for patients.
The cultural anthropologist Margaret Mead once said, “Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.”
As the 12 countries negotiating the Trans-Pacific Partnership (TPP) approach the finish line after years of hard work on an ambitious agreement, there remains quite a bit of work left to be done. Now that all the low hanging fruit has been picked, the most difficult issues remain to be finalized. Not surprisingly, intellectual property (IP) is one of those issues
Across the nation, millions of seniors and disabled Americans have access to innovative medicines through the Medicare prescription drug program (Part D). This year, we’re celebrating the 10-year anniversary of the program’s enactment, as well as taking note of the important feedback provided by those individuals who rely on it.
Every day, our industry strives to connect patients, families and advocates from across the globe who share our common goals of preventing diseases, improving health and saving lives. Those strong voices of innovators and stakeholders working tirelessly to address pressing medical challenges, and many medical breakthroughs wouldn’t be possible today or in the future without them.
In the last 20 years, the Prescription Drug User Fee Act (PDUFA) has resulted in timelier patient access to more than 1,500 new drugs and biologics, decreasing review times for these treatments by more than 60 percent.
We’re excited to host a guest blog post by Steve Pasierb, the passionate CEO of The Partnership at Drugfree.org. We’ve been longtime partners with The Partnership, and Steve’s blog will be the first of regular updates about what’s new in The Partnership at Drugfree.org’s world.
The world’s biopharmaceutical research companies continually strive to develop new medicines that prevent diseases, improve patient health, and help save lives. There are currently more than 5,000 medicines in development globally.
The significant disease progress we've made reminds us to not only recognize and appreciate what we've already accomplished on behalf of patients, but also to look into the future and determine what more can be done.
The best and the brightest spanning the innovation ecosystem have been trying for years to unlock the mysteries of Alzheimer’s disease with the common goals of delaying, treating or outright preventing progression of the disease. Further, there are a number of public and private initiatives underway and no shortage of related conferences and meetings.
In 1992, under the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) began collecting fees from biopharmaceutical companies to provide much needed resources to keep new medicines moving through the approval process and into the hands of patients.